Therapeutic innovation: Inflammatory-reactive astrocytes as targets of inflammation

Elisabeth Hansson a, *, Tony Werner a, Ulrika Björklund a, Eva斯基ödebrand b, c

a Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, SE 413 45, Gothenburg, Sweden
b Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden
c Section of Pathology, Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden

Keywords: Astrocytes, Inflammation, Ca2+ signaling, Actin filament, (−)-Naloxone, (−)-Linalool, Levetiracetam

Abstract

This study aimed to test pharmaceutical compounds targeting astrocytes showing inflammatory dysregulation. The primary rat brain cultures were treated with different batches of serum with or without microglia added to make the cells inflammatory-reactive. Lipopolysaccharide (LPS) and tryptase were used as inflammatory inducers. Expression levels of Toll-like receptor 4 (TLR4), Na+/K+-ATPase, and matrix metalloprotease-13 (MMP-13), as well as actin filament organization, pro-inflammatory cytokines, and intracellular Ca2+ release, were evaluated. LPS combined with tryptase upregulated TLR4 expression, whereas Na+/K+-ATPase expression was downregulated. ATP-evoked Ca2+ transients were increased, actin filaments were reorganized and ring structures instead of stress fibers were observed. Other aims of the study were to prevent astrocytes from becoming inflammatory-reactive and to restore inflammatory dysregulated cellular changes. A combination of the µ-opioid antagonist (−)-naloxone in ultra-low concentrations, the non-addictive µ-opioid agonist (−)-linalool, and the anti-epileptic agent levetiracetam was examined. The results indicated that this drug cocktail prevented the LPS- and tryptase-induced inflammatory dysregulation. The drug cocktail could also restore the LPS- and trypase-treated cells back to a normal physiological level in terms of the analyzed parameters.

© 2016 The Authors. Published by Elsevier Ltd on behalf of International Brain Research Organization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Inflammatory cells are important contributors to the pathophysiological response to injury. Penetration through the blood–brain barrier (BBB) is achieved by circulating bone-marrow-derived leukocytes or monocytes, which can transform into macrophages/microglia. These cells secrete cytokines that promote tissue damage (Medzhitov, 2008; Waisman et al., 2015). The BBB consists of capillary endothelial cells containing specialized tight junctions and surrounded by a basement membrane, which is composed of extracellular matrix components, pericytes and astrocytic perivascular endfeet (Abbott et al., 2006). The gram-negative bacterial endotoxin lipopolysaccharide (LPS) induces the conversion of endothelial cells into activated fibroblasts that show a myofibroblast-like protein profile. This process is mediated by the Toll-like receptor 4 (TLR4)/NF-κB pathway (Sarmiento et al., 2014).

Astrocytes are now known to exert either potent pro-inflammatory functions or crucial protective anti-inflammatory functions that are regulated by specific signaling inputs (Hansson, 2010; Zeng et al., 2013; Hansson and斯基ödebrand, 2015). Their processes establish contacts with the BBB and the processes of other astrocytes via gap junctions, thereby forming networks of coupled astrocytes (Cornell-Bell et al., 1990; Blomstrand et al., 1999; Guthrie et al., 1999; Nedergaard et al., 2003). At sites of CNS tissue damage, astrocytes become reactive and form scar borders, which serve as functional barriers and have the potential to release diverse molecules that affect nearby cells. Astrocyte dysfunction can be caused by genetic polymorphisms or by exposure to molecular signals derived from infections or trauma, which can alter astrocyte inflammatory regulation and lead to detrimental effects (Sofroniew, 2015), including the alteration of astrocyte signaling mechanisms (Hansson, 2010, 2015).
LPS as a potent inflammatory activator in astrocytes, has shown to give good results (Forshammar et al., 2011; Block et al., 2012, 2013). However, better inflammatory-induced activity is desired as the mechanisms of actions in the restoration processes are desired to be better expressed.

Mast cells are derived from the bone marrow and play important roles in inflammation, immune responses and tissue repair. They circulate in an immature form until they reach the target tissue site (Skaper et al., 2013). Mast cells are rich in proteases, tryptases and chymases, as well as cytokines such as interleukins, TGFβ and tumor necrosis factor-α (TNF-α). They contact only blood vessels that are ensheathed by astroglial processes, and they can alter the BBB permeability and pass into the CNS (Kahli et al., 2007; Dong et al., 2014). They can upregulate purinergic receptors on astrocytes (Dong et al., 2014) and activate the G protein-coupled protease-activated receptor (PAR-2) in astrocytes by releasing tryptase (Zeng et al., 2013).

Matrix metalloproteinases (MMPs or matrixins) activate signal transduction pathways that control cytokine biosynthesis and barrier immunity. MMP-13, which is produced by both neurons and astrocytes, is upregulated in response to inflammation in the brain, and it remodels the extracellular matrix and degrades substrates as part of the neuroinflammatory response (Cuadrado et al., 2009).

The first aim of the present study was to test different substances of relevance to get astrocytes more inflammatory-reactive and 2) prevent astrocytes from becoming in inflammatory-reactivity. The astrocyte cultures were treated with different batches of serum with or without microglia. Furthermore, LPS and trypstatne were applied in combination. Cellular changes were analyzed according to several parameters, such as expression of TLR4, Na+/K+-ATPase, and MMP-13, as well as actin filament organization, pro-inflammatory cytokine levels, and intracellular Ca2+ release. The second aims were to 1) prevent astrocytes from becoming inflammatory-reactive and 2) restore cellular changes and disturbances, which already were inflammatory-reactive back to physiological levels. We have earlier shown that a combination of a μ-opioid receptor antagonist in ultra-low concentrations, naloxone, a μ-opioid agonist, endomorphin-1, and an agent attenuating IL-1β release, levetiracetam, can restore cellular parameters induced by inflammation. The responses have been tested in astrocytes (Block et al., 2013) and in post-surgical neuropathic pain patients in vivo (Block et al., 2015). We wanted now to replace endomorphin-1/morphine with the non-addictive μ-opioid agonist (−)-linalool and evaluate if this substance had similar restorative effects as endomorphin-1.

2. Materials and methods

The studies were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) revised 1996 or the UK Animals (Scientific Procedures) Act 1986 and associated guidelines, or the European Communities Council Directive of 24 November 1986 (86/609/EEC).

2.1. Primary astrocyte cultures and treatments

Primary cortical astrocytes, from Sprague–Dawley rats at embryonic day 19, were purchased from Invitrogen (Thermo Fisher Scientific, Waltham, MA, USA) and prepared according to the manufacturer’s instructions with some modifications. Briefly, one vial containing 1 × 10^6 viable cells were plated at a seeding density of 1 × 10^4 cells per cm² on uncoated glass coverslips (no. 1. 20 mm in diameter) (Bergman Labora, Stockholm, Sweden) and placed in 12-well plates. The medium was replaced twice per week. The astrocytes were used after 16–17 days in culture.

2.2. Chemicals

All chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated.

2.3. Inflammatory-reactive substances added to astrocyte cultures

Cultures were treated with two different batches of serum: 15% fetal bovine serum from Invitrogen, called astroglia serum, or 15% fetal bovine serum (Biochem AG, Berlin, Germany) called microglia serum, as it was used to increase the amount of microglia (Persson et al., 2005). Some cultures were shaken to promote growth of microglia. Exogenous microglia were added to the astrocyte cultures.

LPS (10 ng/ml) (Forshammar et al., 2011), which was used to promote inflammatory reactivity, was added 24 h before the experiments. To further increase the inflammatory reactivity, trypstatne (10 ng/ml) (Zeng et al., 2013) was added together with LPS 24 h before the experiments.

2.4. Immunocytochemistry

Immunocytochemistry was done according to Block et al. (2013). Glial fibrillary acidic protein (GFAP) (Dako, Glostrup, Denmark) and a mouse monoclonal antibody against OX42 (Sero- tec, Oxford, UK) were used. The cells were viewed using a Nikon Eclipse 80i microscope. Pictures were taken with a Hamamatsu C5810 color-intensified 3CCD camera.

2.5. Viability assay

A LIVE/DEAD viability assay kit (Invitrogen Molecular Probes) for mammalian cells was used according to Forshammar et al. (2011), viewed using a Nikon Eclipse 80i microscope. Pictures were taken with a Hamamatsu C5810 color-intensified 3CCD.

2.6. Calcium imaging

Calcium imaging was done as earlier described (Block et al., 2013). The total areas under the curve (AUC), which reflects the amount of Ca2+ released (Berridge, 2007), were analyzed. The amplitude was expressed as the maximum increase of the 340/380 ratio. The area under the Ca2+ peaks (AUC) was calculated in Origin (Microcal Software Inc., Northampton, MA, USA). Forty cells were used for each experimental set-up and were taken from four different coverslips and from two different seeding times.

2.7. SDS-PAGE and western blot

SDS-page and western blot were done as earlier described (Block et al., 2013).

2.8. Actin visualization

The astrocyte cytoskeleton was stained using Alexa™488-conjugated phalloidin (Invitrogen) (Block et al., 2013).

2.9. Actin assay

Actin quantitation was performed as recommended by the F-actin/G-actin In Vivo Assay Biochem Kit (Cytoskeleton, Inc., Denver, CO, USA) and SDS-page performed as described above, with the exception of the sample preparation. The primary antibody, rabbit polyclonal anti-actin (Cytoskeleton, 1:500), and the secondary antibody, HRP-conjugated donkey anti-rabbit IgG F(ab’)2 fragments.
in Na⁺ showed an increase in TLR4 expression (Fig. 2).

2.10. Cytokine release

Rat IL-1β (R&D Systems, Oxon, UK) and TNF-α (Becton Dickinson, NJ, USA) were used to measure the amounts of cytokines via ELISA according to the manufacturer’s instructions.

2.11. Protein determination

A protein determination assay was performed in accordance with the manufacturer’s instructions using a detergent-compatible (DC) Protein Assay (Bio-Rad, Hercules, CA, USA) and based on the method used by Lowry et al. (1951).

2.12. Statistics

Statistical significance was determined using Student’s paired t-test or one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test. The error bars represent the standard error of the mean (SEM).

3. Results

3.1. Activation of astrocytes to become inflammatory-reactive

3.1.1. Different batches of serum and/or addition of microglia

The results show that cultivating the astrocytes used in the present experiments, which is cells bought from a company, in different serum batches or shaking the cultures in different ways to stimulate microglia growth did not increase the inflammatory reactivity as evaluated with the present parameters. This was, however, not the case with our previous astrocytes made by ourselves (Hansson et al., 1984). Furthermore, addition of external microglia to the present astrocyte cultures did not increase the inflammatory reactivity of the astrocytes.

In all further experiments, the cells were cultivated with astroglia serum without the addition of exogenous microglia.

3.1.2. Astrocytes incubated with LPS or LPS and tryptase

Cultures were stained for OX42, a marker for microglial cells, and for GFAP, a marker for astrocytes. Very few or no microglia were found in the control cultures or in cultures treated with LPS for 24 h or with LPS + tryptase for 24 h (Fig. 1). There were small differences among the groups in the viability of the cells visualized with a LIVE/DEAD kit (Fig. 2).

Astrocyte cultures were incubated with LPS for 24 h. They showed an increase in TLR4 expression (P < 0.05) (Fig. 3), a decrease in Na⁺/K⁺-ATPase expression (P < 0.001) (Fig. 4), and no change in MMP-13 expression (Fig. 5). Furthermore, the cells were stimulated with ATP (10⁻⁴ M), which increased the ATP-evoked Ca²⁺ transients, AUC, (P < 0.001) (Fig. 6). The astrocytes were stained with an Alexa488-conjugated phalloidin probe. The untreated cultures were dominated by F-actin organized in stress fibers (control). The cultures incubated with LPS showed a more diffuse organization of actin filaments, and the ring structures were more pronounced (Fig. 7). They also showed morphologic changes, including the retraction of cell bodies and changes in the stress fiber distribution. Therefore, the F/G actin ratio was calculated, and it was increased in the cells treated with LPS (P < 0.01) (Fig. 9).

Astrocyte cultures were incubated with LPS + tryptase for 24 h. They showed an increase in TLR4 expression (P < 0.05) (Fig. 3), a decrease in Na⁺/K⁺-ATPase expression (P < 0.01) (Fig. 4), and no change in MMP-13 expression (Fig. 5). Furthermore, the cells were stimulated with ATP (10⁻⁴ M), the ATP-evoked Ca²⁺ transients increased, AUC, (P < 0.01) (Fig. 6). The cells changed their morphology in comparison to astrocytes incubated with only LPS (Fig. 7), and the F/G actin ratio was increased in the cells treated with LPS and tryptase (P < 0.001) (Fig. 9).

None of the above combinations showed release of IL-1β or TNF-α.

3.2. Prevent LPS- and tryptase-induced biochemical changes in astrocytes with the combination of (−)-naloxone, (−)-linalool and leviteracetam

Astrocytes were incubated with a cocktail of naloxone (10⁻¹² M), (−)-linalool (10⁻⁶ M), and leviteracetam (10⁻⁶ M) for 30 min. The incubation continued with the cocktail and LPS or with the cocktail and LPS + tryptase for 24 h. The TLR4 expression was decreased when incubated with the cocktail, which showed the same expression level as the control cells. The cocktail prevented the cells to become inflammatory-reactive. The Na⁺/K⁺-ATPase expression was increased, whereas MMP-13 expression did not change (Fig. 8). The F/G actin ratio was calculated and was increased in the cells treated with LPS (P < 0.01) or LPS + tryptase (P < 0.001) but was decreased in the presence of the cocktail (Fig. 9). The actin filaments were prevented from reorganization.

3.3. Restore LPS- and tryptase-induced biochemical changes in astrocytes with the combination of (−)-naloxone, (−)-linalool and leviteracetam

Astrocytes were incubated with LPS + tryptase for 24 h. Then, the incubation continued with LPS + tryptase and the cocktail of naloxone (10⁻¹² M), (−)-linalool (10⁻⁶ M), and leviteracetam (10⁻⁶ M) for an additional 24 h. The expression levels of TLR4, Na⁺/K⁺-ATPase, and MMP-13 were then analyzed (Fig. 10). The cocktail restored the increased expression of TLR4 to the control level. A

![Fig. 1](image-url). Culture stained for OX42, a marker for microglial cells (green), and for GFAP, a marker for astrocytes (red). A. Very few microglia were found in the control cultures. B. Similarly, very few microglia were found after treatment with LPS for 24 h or with C. LPS + tryptase for 24 h. Scale bar = 50 μm. Representative images are presented.
Fig. 2. Cell viability was visualized with Calcein AM (green) using a LIVE/DEAD kit and showed very few dead cells, shown with red nuclei in figure (A). The viability did not change after incubation with LPS (B) or with LPS and tryptase (C). Scale bar = 50 μm. Representative images are presented.

Fig. 3. TLR4 expression. Astrocytes were incubated with LPS (10 ng/ml) for 24 h or with LPS (10 ng/ml) and tryptase (100 ng/ml) for 24 h. The expression of TLR4 was increased compared with the control. The level of significance was analyzed using a one-way ANOVA followed by Dunnett’s multiple comparisons test. *P < 0.05. n = 5.

Fig. 4. Na⁺/K⁺-ATPase expression. Astrocytes were incubated with LPS (10 ng/ml) for 24 h or with LPS (10 ng/ml) and tryptase (100 ng/ml) for 24 h. The Na⁺/K⁺-ATPase expression was decreased compared with the control. The level of significance was analyzed using a one-way ANOVA followed by Dunnett’s multiple comparisons test. *P < 0.05. **P < 0.01. n = 5.

Fig. 5. MMP-13 expression. Astrocytes were incubated with LPS (10 ng/ml) for 24 h or with LPS (10 ng/ml) and tryptase (100 ng/ml) for 24 h. The MMP-13 expression was not significantly changed. The level of significance was analyzed using a one-way ANOVA followed by Dunnett’s multiple comparisons test. n = 5.

Fig. 6. ATP-evoked Ca²⁺ transients. All astrocytes were stimulated in a Ca²⁺ imaging system. The cells were incubated with a Ca²⁺-sensitive fluorophore probe (Fura-2/AM), ATP (10⁻⁶ M) elicited Ca²⁺ responses in the astrocytes and was used as the control. The area under the Ca²⁺ peak (AUC) was calculated for each Ca²⁺ transient. The cells incubated with LPS (10 ng/ml) for 24 h showed increased Ca²⁺ signaling, as did the cells incubated with LPS (10 ng/ml) and tryptase (100 ng/ml) for 24 h. The level of significance was analyzed using a one-way ANOVA followed by Dunnett’s multiple comparisons test. **P < 0.01, ***P < 0.001. n = 5.
similar effect was seen for Na\(^+\)/K\(^+\)-ATPase, but MMP-13 expression did not change. The F/G actin ratio was calculated and was increased in the cells treated with LPS (P < 0.05) and LPS + tryptase (P < 0.001) compared to their respective controls. The cocktail decreased the ratio back to the control level (Fig. 11).

### 3.3.1. Glutamate-evoked Ca\(^{2+}\) responses were increased with LPS and attenuated by the combination of naltroxone, (−)-linalool and levetiracetam

Glutamate (10\(^{-4}\) M) was used as a stimulator in the Ca\(^{2+}\) imaging experiments, in which all cells responded (n = 40). The AUC was calculated for each condition (Fig. 12).
one-way ANOVA followed by Dunnett’s multiple comparisons test. *P < 0.05, **P < 0.01, n.s. — non-significant. n = 4.

![Fig. 10. Restore LPS- and tryptase-induced biochemical changes in astrocytes with the combination of (−)naloxone, (−)linalool and levetiracetam. Astrocytes were incubated with LPS (10 ng/ml) + tryptase (100 ng/ml) for 24 h. Then, the cells were incubated with LPS + tryptase and the cocktail of naloxone (10⁻⁵ M), (−)linalool (10⁻⁶ M), and levetiracetam (10⁻⁴ M) for an additional 24 h. The expression levels of TLR4, Na⁺/K⁺-ATPase and MMP-13 were studied using western blot analysis. The level of significance was analyzed using one-way ANOVA followed by Dunnett’s multiple comparisons test. *P < 0.05, **P < 0.01, n.s. — non-significant. n = 4.](image)

![Fig. 11. Actin filaments. Astrocytes were incubated with LPS (10 ng/ml) (A) or LPS + tryptase (100 ng/ml) (B) for 24 h. Then, the incubation continued with LPS and the cocktail of naloxone (10⁻⁵ M), (−)linalool (10⁻⁶ M), and levetiracetam (10⁻⁴ M) for an additional 24 h (A), or with LPS + tryptase and the cocktail for an additional 24 h (B). The F/G actin ratio was measured. The ratio was increased in the cells treated with LPS and tryptase but decreased when the cells were stimulated with the cocktail. The level of significance was analyzed using one-way ANOVA followed by Dunnett’s multiple comparisons test. *P < 0.05, **P < 0.01, n.s. — non-significant. n = 4.](image)

included endomorphin-1 instead of (−)-linalool. The present results show that endomorphin-1 can be replaced by the non-addictive µ-agonist (−)-linalool.

4. Discussion

Inflammation in the CNS differs from inflammation elsewhere in the body because of the sensitivity and isolation of the CNS. Microglia produce anti-inflammatory and neurotrophic factors under physiological conditions and produce pro-inflammatory mediators in response to infection or tissue damage (Streit, 2002). These act on astrocytes that in turn amplify the inflammatory reaction (Sajo et al., 2009). Therefore, microglia and astrocytes are of particular interest because both cell types can initiate and amplify inflammation and thereby release neurotoxic compounds. Therefore, an in vitro cell model system of inflammation is desirable for studying potential treatments, which is even better than the one used by us in earlier experiments (Block et al., 2013).

The astrocyte cultures were investigated using different cultivation parameters. Two different fetal calf sera were used to promote microglial growth. Furthermore, the cultures were shaken to recruit more microglia. Microglia from external cultures were also added. We hypothesized that the number of microglia and/or the reactivity of these cells could make the astrocytes inflammatory-reactive (DeLeo et al., 2004; Milligan and Watkins, 2009). Our results show that astrocytes and microglia are not capable of initiating inflammation by themselves, but microglia do appear to be at least partly responsible for the changes induced in known biomarkers, with a stronger induction of TLR4 and reduced expression of Na⁺/K⁺-ATPase, but without the release of pro-inflammatory cytokines.

Previous studies have produced inflammatory-reactive astrocytes with LPS or IL-1β (Forshammar et al., 2011; Lundborg et al., 2011; Block et al., 2012). Mast cells are active in vivo during inflammation and release serine proteases such as tryptase (Medzhitov, 2008). Therefore, we expanded our inflammatory potential combining LPS with tryptase. The tryptase-activated receptor 2 (PAR-2) is well known to be widely expressed on astrocytes and to play a major role in inflammation (Zeng et al., 2013).

TLRs, which recognize structural motifs that are characteristic of pathogens and which are expressed by innate immune cells (Janeway and Medzhitov, 2002), are gaining increasing recognition for their roles in several inflammatory diseases. LPS has been shown to be an agonist for TLR4 (Qureshi et al., 1999), which is thought to be largely responsible for LPS-related signaling (Kielen, 2006). It has been proposed that TLRs drive inflammation that gives rise to detectable symptoms (O’Neill, 2003; Krasowska-Zoladek et al., 2007). Astrocytes express TLR4, which is further induced after incubation with LPS (Forshammar et al., 2011) or with the combination of LPS and tryptase.

Three Na⁺ ions are required for the uptake of one glutamate, and this transport is dependent on the intra- and extracellular concentrations of Na⁺ (Longuemare et al., 1999). The intracellular...
A cocktail of naloxone, (−)-linalool and levetiracetam was used for two purposes. First, to prevent network-coupled astrocytes from becoming inflammatory-reactive. Second, to restore already inflammatory-reactive networks.

Naloxone, a non-selective μ-opioid antagonist, and a (−)-isomer, normally blocks the G_{i/o}/G_{o} protein associated with the μ-opioid receptor. However, in ultra-low concentrations, naloxone blocks the G_{o} protein instead (Block et al., 2012). Chronic morphine administration decreases G_{i/o}/G_{o} protein coupling and increases coupling to the G_{o} protein. This phenomenon has been observed in cultured dorsal root ganglion neurons (Crain and Shen, 1995), rat brain organotypic cultures (Wang and Burns, 2009), in vivo in rats (Wang et al., 2005), and in patients treated for low back pain (Block et al., 2015). Ultra-low concentrations of naloxone can block the G_{o} protein, and morphine or another μ-opioid receptor agonist can thereby stimulate the G_{i/o}/G_{o} protein (Block et al., 2013; Hansson, 2015). However, it is worth knowing that another form of naloxone exists. The inactive (+)-isomer of naloxone, which has no antagonistic effects on opioid receptors, has been shown to be an antagonist of TLR4 and to block the downstream signaling leading to the production of nitric oxide (NO), TNF-α and reactive oxygen species (ROS) (Wang et al., 2015).

An important aim with the present study was to replace endomorphin-1/morphine with a non-addictive μ-opioid agonist (Block et al., 2013). Linalool, (3,7-dimethyl-1,6-octadien-3-ol), a monoterpene, along with its naturally occurring enantiomer (+)-linalool alone, or linalool, or levetiracetam (cocktail) attenuated the glutamate signaling. The level of significance was analyzed using a one-way ANOVA followed by Dunnett’s multiple comparisons test. *P < 0.05, ***P < 0.001, n.s. = non-significant. n = 5.

Fig. 12. Glutamate-evoked Ca^{2+} transients. All astrocytes were stimulated in a Ca^{2+} imaging system. The cells were incubated with a Ca^{2+}-sensitive fluorophore (Fura-2/AM). Glutamate (10^{-4} M) elicited Ca^{2+} responses in the astrocytes and was used as a control. The area under the Ca^{2+} peak (AUC) was calculated for each Ca^{2+} transient. The cells incubated with LPS (10 ng/ml) for 24 h showed increased Ca^{2+} signaling. The cells incubated with LPS (10 ng/ml) for 24 h and then (−)-naloxone (10^{-12} M), (−)-linalool (10^{-6} M), levetiracetam (10^{-4} M), or a combination of the three substances was applied 3.5 min before glutamate stimulation. (−)-linalool alone, (−)-naloxone alone or together with (−)-linalool, or levetiracetam alone did not attenuate the glutamate-aggregated Ca^{2+} transients. The combination of (−)-naloxone, (−)-linalool, and levetiracetam (cocktail) attenuated the glutamate signaling. The level of significance was analyzed using a one-way ANOVA followed by Dunnett’s multiple comparisons test. *P < 0.05, ***P < 0.001, n.s. = non-significant. n = 5.

concentration of Na^{+} is maintained by Na^{+}/K^{+}-ATPase and is dependent on ATP (Longuemare et al., 1999). The present study showed a decrease in Na^{+}/K^{+}-ATPase expression, which was further decreased after the combined treatment with LPS and tryptase.

No changes were observed in the expression of the latent proenzyme form of MMP-13, and no active form of MMP-13 was detected.

In conditions that lead to chronic neuroinflammation, Ca^{2+} signaling in astrocyte networks is overactivated (Hansson, 2010, 2015; Forshammar et al., 2011). Regulation of Ca^{2+} dynamics by transmitters and soluble factors is a possible mechanism by which the astrocyte networks detect changes in the CNS microenvironment and regulate brain activity, such as inflammatory processes. LPS changed the ATP-evoked Ca^{2+} transients with increased intracellular Ca^{2+} release. Intercellular Ca^{2+} communication takes place through gap junctions, and the parallel system for intercellular Ca^{2+} communication between astrocytes occurs via extracellular communication through the diffusion of ATP (Fields and Burnstock, 2006). ATP then binds to purinoceptors, specifically P2Y-receptors, which leads to an overstimulation of the G_{q} protein, and subsequent elevations of intracellular Ca^{2+} waves are observed (Blomstrand et al., 1999).

Cells treated with LPS or LPS + tryptase displayed reorganization of their stress fibers and induced formation of ring structures that resulted in an increased F/G actin ratio, which was also confirmed using phalloidin staining. Reorganization of F-actin into different contractile structures such as apical rings, vacuoles, or stress fiber-like cables that are more or less diffuse was observed in our previous study (Hansson, 2015), as well as in epithelial cells (Ivanov et al., 2010), pulmonary monocytes (Du et al., 2012), and vascular smooth muscle cells (Kim et al., 2008).
Ca\(^{2+}\) release. Glutamate is a transmitter with inflammatory properties (Hansson, 1994; Hansson et al., 1994; Milligan and Watkins, 2009). Therefore we reasoned that a further decrease might be of importance. These results were obtained with endomorphin-1 in the cocktail (Block et al., 2013) and with (--)linalool in the cocktail in the present study.

The next questions and challenges are, of course, whether the cocktail has anti-inflammatory or restorative effects in humans. We have used an ultra-low dose of intrathecal naloxone in addition to intrathecal morphine infusion in patients with severe, persistent pain, which improved the perceived quality of sleep and where conventional pain therapies are insufficient. We were not able to show any statistically significant effects of naloxone on pain relief due to the short treatment time and a small sample size: however, some of the patients in the group reported pain relief (Block et al., 2015; Block, 2016). The next step is to evaluate the present pharmaceutical combination in patients with chronic inflammation and longterm pain for longer time than previously done. Substantial progress has been made in understanding how chronic systemic low-grade inflammation influences the physiology of several diseases such as neuroinflammation, neurodegenerative diseases, osteoarthritis, metabolic, cardiac inflammation and autoimmune diseases, but not why it fails to be resolved (Lecuyer et al., 2015). The physiological nature of inflammation has been gaining ground as a key contributor and search for inflammatory markers is required. Inflammation requires contribution from other tissue cells such as gap junction coupled cells (Hansson and Sköledébrand, 2015).

Conclusion: Inflammatory reactivity in astrocytes was achieved with a combination of LPS and tryptase. The pharmaceutical compounds, (--)linalool, naloxone in ultra-low concentrations, and the anti-epileptic agent levetiracetam, showed the ability to both antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic treatment. Proc. Natl. Acad. Sci. U. S. A. 92, 10540–10544.


Persson, M., Brantefjord, M., Hansson, E., Ronnback, L., 2005. Lipopolysaccharide increases microglial GLT-1 expression and glutamate uptake capacity in vitro by a mechanism dependent on TNF-α. GLIA 51, 111–120.